Results from a sleep study indicate a reduced circadian rhythmicity is associated with an increased risk for incident Parkinson disease.
Researchers examined the association between fractures and Parkinson disease during the prodromal period.
Higher doses of deutetrabenazine appear to be safe and well tolerated in patients with Huntington disease who may require them to adequately control chorea.
Treatment with deutetrabenazine was found to be beneficial for both younger (<55 years) and older (≥55 years) patients with tardive dyskinesia, according to findings from a recently published post hoc analysis.
The etiology and management of peripheral neuropathy in Parkinson disease is discussed.
The FDA has accepted for review the supplemental New Drug Application for Gocovri® for the treatment of off episodes in Parkinson disease patients receiving levodopa-based therapy.
A study found a causally protective effect of tobacco smoking on the risk of Parkinson disease.
This sublingual film formulation of apomorphine was designed for use as a fast-acting, on-demand treatment for all types of motor off episodes.
A study finds that a majority of patients with Parkinson disease report difficulties in achieving early detection of their disease.
Precision medicine offers a promising therapeutic strategy for patients with Parkinson disease, allowing for tailored treatments which reflect the unique pathophysiology in each patient.